Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
Total Valuation
Centessa Pharmaceuticals has a market cap or net worth of $1.79B. The enterprise value is ―.
Market Cap$1.79B
Enterprise Value―
Share Statistics
Centessa Pharmaceuticals has 133,618,770 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding133,618,770
Owned by Insiders1.01%
Owned by Institutions69.98%
Financial Efficiency
Centessa Pharmaceuticals’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -39.23%.
Return on Equity (ROE)-0.59
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-39.23%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-3.06M
Employee Count77
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Centessa Pharmaceuticals is -8.13. Centessa Pharmaceuticals’s PEG ratio is 0.00.
PE Ratio-8.13
PS Ratio0.00
PB Ratio0.00
Price to Fair Value4.78
Price to FCF-264.70
Price to Operating Cash Flow-264.70
PEG Ratio0.00
Income Statement
In the last 12 months, Centessa Pharmaceuticals had revenue of 0.00 and earned -235.76M in profits. Earnings per share was -2.06.
Revenue0.00
Gross Profit-942.00K
Operating Income-201.06M
Pretax Income-233.01M
Net Income-235.76M
EBITDA-221.97M
Earnings Per Share (EPS)-2.06
Cash Flow
In the last 12 months, operating cash flow was -162.01M and capital expenditures -34.00K, giving a free cash flow of -162.05M billion.
Operating Cash Flow-162.01M
Free Cash Flow-162.05M
Free Cash Flow per Share-1.21
Dividends & Yields
Centessa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change45.21%
50-Day Moving Average12.76
200-Day Moving Average15.26
Relative Strength Index (RSI)56.15
Average Volume (3m)1.04M
Important Dates
Centessa Pharmaceuticals upcoming earnings date is Aug 18, 2025, Before Open (Confirmed).
Last Earnings DateMay 14, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Centessa Pharmaceuticals as a current ratio of 9.25, with Debt / Equity ratio of 0.00%
Current Ratio9.25
Quick Ratio9.25
Debt to Market Cap0.06
Net Debt to EBITDA1.20
Interest Coverage Ratio-19.92
Taxes
In the past 12 months, Centessa Pharmaceuticals has paid 2.84M in taxes.
Income Tax2.84M
Effective Tax Rate-0.01
Enterprise Valuation
Centessa Pharmaceuticals EV to EBITDA ratio is -7.44, with an EV/FCF ratio of -11.62.
EV to Sales0.00
EV to EBITDA-7.44
EV to Free Cash Flow-11.62
EV to Operating Cash Flow-11.63
Balance Sheet
Centessa Pharmaceuticals has $284.50M in cash and marketable securities with $8.12M in debt, giving a net cash position of -$276.39M billion.
Cash & Marketable Securities$284.50M
Total Debt$8.12M
Net Cash-$276.39M
Net Cash Per Share-$2.07
Tangible Book Value Per Share$3.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Centessa Pharmaceuticals is $32.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.57
Price Target Upside142.52% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-100.00%
EPS Growth Forecast-25.86%